Marketing

Overseas Activities

MR

As a leading company for Glycyrrhizin preparation, Minophagen Pharmaceutical Co., Ltd. has been marketing its pharmaceutical products not only in Japan, but also in 8 foreign countries (China, Taiwan, Korea, India, Indonesia, Mongolia, Uzbekistan and Armenia).

Stable supply to the Chinese market, the largest in the world.

In China, the largest number of patients suffering from viral hepatitis in the world, "Stronger Neo-Minophagen C" and "Glycyron Tablets" were approved in 1996 and have been marketed there since 1997. In the same year, we set up a representative office in Beijing. In China, there are about one hundred and seventy million viral careers suffering from chronic hepatitis. We will continue to offer high quality products and contribute to Chinese patient’s health.

Inroads into CIS countries

To satisfy the unmet medical needs of patients throughout the world, we have taken up the challenge of developing our business more extensively in emerging countries around the world. We secured the approval of "Stronger Neo-Minophagen C" and "Glycyron Tablets" in Armenia and Georgia in 2010, as well as in Moldova in 2013. We are continuing to take up the challenge of contributing to the future of patients who are looking forward to better health in Russia, as well as in the CIS countries.

Cooperation with alliance partners

We have been focusing our attention on development in Southeast Asia, in addition to the countries (India, Indonesia, Korea and Taiwan) where our products are already being marketed. In particular, we will proceed with the development of "Stronger Neo-Minophagen C" by cooperating with alliance partners. We will continue to contribute to community medicine in Asian countries by providing high quality products to its extensive regions.

Page Top